pharma · Moderately to Severely Active Rheumatologic Disease · Moderately to Severely Active Ulcerative Colitis · SYRE
Spyre Therapeutics
Spyre Therapeutics trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
Waltham, USA HQ
2023 Founded
110 Employees
Public company Type
SYRE · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2023
- Employees
- 110
- Programs
- 8
- Drugs
- 1
- Patents
- 0
Spyre Therapeutics clinical trials
Registry index of 8 ClinicalTrials.gov studies linked to Spyre Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.
Spyre Therapeutics trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Spyre Therapeutics.
-
SPY123-201 — Phase 2
Clinical update -
SPYPBO-101 Placebo to SPY072, SPY072 — Phase 2
Clinical update -
SPY001 — Phase 2
Clinical update -
SPY002-072 — Phase 2
Clinical update -
SPY001-001 — Phase 1
Clinical update -
SPY002-072 — Phase 1
Clinical update -
SPY002-091 — Phase 1
Clinical update -
SPY003-207 — Phase 1
Clinical update
Trial registry
-
CTIS ↗ - 2025-521791-63-00CTIS ↗
SPYPBO-101 Placebo to SPY072, SPY072
Moderately to Severely Active Rheumatologic Disease
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗